Literature DB >> 26109259

Ketogenic diets in patients with inherited metabolic disorders.

S Scholl-Bürgi1, A Höller, K Pichler, M Michel, E Haberlandt, D Karall.   

Abstract

Ketogenic diets (KDs) are diets that bring on a metabolic condition comparable to fasting, usually without catabolism. Since the mid-1990s such diets have been widely used in patients with seizures/epilepsies, mostly children. This review focuses on the use of KDs in patients with various inherited metabolic disorders (IMD). In glucose transporter type 1 deficiency syndrome (GLUT1-DS) and pyruvate dehydrogenase complex (PDHc) deficiency, KDs are deemed the therapy of choice and directly target the underlying metabolic disorder. Moreover, in other IMD, mainly of intermediary metabolism such as glycogen storage diseases and disorders of mitochondrial energy supply, KDs may ameliorate clinical symptoms and laboratory parameters. KDs have also been used successfully to treat symptoms such as seizures/epilepsy in IMD, e.g. in urea cycle disorders and non-ketotic hyperglycinemia. As a note of caution, catabolism may cause the condition of patients with IMD to deteriorate and should thus be avoided during KDs. For this reason, careful monitoring (clinical, laboratory and apparatus-supported) is warranted. In some IMDs specific macronutrient supply is critical. Therefore, in cases of PDHc deficiency the carbohydrate intake tolerated without lactate increase and in urea cycle disorders the protein tolerance should be determined. Considering this, it is particularly important in patients with IMD that the use of KDs be individualized and well documented.

Entities:  

Mesh:

Year:  2015        PMID: 26109259     DOI: 10.1007/s10545-015-9872-2

Source DB:  PubMed          Journal:  J Inherit Metab Dis        ISSN: 0141-8955            Impact factor:   4.982


  60 in total

Review 1.  Mitochondrial disease and epilepsy.

Authors:  Shamima Rahman
Journal:  Dev Med Child Neurol       Date:  2012-01-28       Impact factor: 5.449

2.  Fasting versus gradual initiation of the ketogenic diet: a prospective, randomized clinical trial of efficacy.

Authors:  A G Christina Bergqvist; Joan I Schall; Paul R Gallagher; Avital Cnaan; Virginia A Stallings
Journal:  Epilepsia       Date:  2005-11       Impact factor: 5.864

3.  Caveats when considering ketogenic diets for the treatment of pyruvate dehydrogenase complex deficiency.

Authors:  T A Weber; M R Antognetti; P W Stacpoole
Journal:  J Pediatr       Date:  2001-03       Impact factor: 4.406

4.  The clinical phenotype of succinic semialdehyde dehydrogenase deficiency (4-hydroxybutyric aciduria): case reports of 23 new patients.

Authors:  K M Gibson; E Christensen; C Jakobs; B Fowler; M A Clarke; G Hammersen; K Raab; J Kobori; A Moosa; B Vollmer; E Rossier; A K Iafolla; D Matern; O F Brouwer; J Finkelstein; F Aksu; H P Weber; J A Bakkeren; F J Gabreels; D Bluestone; T F Barron; P Beauvais; D Rabier; C Santos; W Lehnert
Journal:  Pediatrics       Date:  1997-04       Impact factor: 7.124

5.  A modified Atkins diet is promising as a treatment for glucose transporter type 1 deficiency syndrome.

Authors:  Yasushi Ito; Hirokazu Oguni; Susumu Ito; Miyako Oguni; Makiko Osawa
Journal:  Dev Med Child Neurol       Date:  2011-04-18       Impact factor: 5.449

6.  Ketogenic diet slows down mitochondrial myopathy progression in mice.

Authors:  Sofia Ahola-Erkkilä; Christopher J Carroll; Katja Peltola-Mjösund; Valtteri Tulkki; Ismo Mattila; Tuulikki Seppänen-Laakso; Matej Oresic; Henna Tyynismaa; Anu Suomalainen
Journal:  Hum Mol Genet       Date:  2010-02-17       Impact factor: 6.150

Review 7.  Mitochondrial DNA depletion syndromes: review and updates of genetic basis, manifestations, and therapeutic options.

Authors:  Ayman W El-Hattab; Fernando Scaglia
Journal:  Neurotherapeutics       Date:  2013-04       Impact factor: 7.620

8.  Ketogenic treatment reduces deleted mitochondrial DNAs in cultured human cells.

Authors:  Sumana Santra; Robert W Gilkerson; Mercy Davidson; Eric A Schon
Journal:  Ann Neurol       Date:  2004-11       Impact factor: 10.422

9.  Energy substrate metabolism in pyruvate dehydrogenase complex deficiency.

Authors:  Maria Halldin Stenlid; Fredrik Ahlsson; Anders Forslund; Ulrika von Döbeln; Jan Gustafsson
Journal:  J Pediatr Endocrinol Metab       Date:  2014-11       Impact factor: 1.634

10.  Modified Atkins diet therapy for a case with glucose transporter type 1 deficiency syndrome.

Authors:  Susumu Ito; Hirokazu Oguni; Yasushi Ito; Keiko Ishigaki; Junko Ohinata; Makiko Osawa
Journal:  Brain Dev       Date:  2007-09-14       Impact factor: 1.961

View more
  17 in total

1.  Ketones and inborn errors of metabolism: old friends revisited.

Authors:  Rob C I Wüst; Gepke Visser; Ronald J A Wanders; Riekelt H Houtkooper
Journal:  J Inherit Metab Dis       Date:  2017-01       Impact factor: 4.982

2.  Enzymatic testing sensitivity, variability and practical diagnostic algorithm for pyruvate dehydrogenase complex (PDC) deficiency.

Authors:  Ha Kyung Shin; George Grahame; Shawn E McCandless; Douglas S Kerr; Jirair K Bedoyan
Journal:  Mol Genet Metab       Date:  2017-09-08       Impact factor: 4.797

Review 3.  Multi-dimensional Roles of Ketone Bodies in Fuel Metabolism, Signaling, and Therapeutics.

Authors:  Patrycja Puchalska; Peter A Crawford
Journal:  Cell Metab       Date:  2017-02-07       Impact factor: 27.287

Review 4.  Lethal neonatal case and review of primary short-chain enoyl-CoA hydratase (SCEH) deficiency associated with secondary lymphocyte pyruvate dehydrogenase complex (PDC) deficiency.

Authors:  Jirair K Bedoyan; Samuel P Yang; Sacha Ferdinandusse; Rhona M Jack; Alexander Miron; George Grahame; Suzanne D DeBrosse; Charles L Hoppel; Douglas S Kerr; Ronald J A Wanders
Journal:  Mol Genet Metab       Date:  2017-02-02       Impact factor: 4.797

5.  Current progress in the therapeutic options for mitochondrial disorders.

Authors:  E Koňaříková; A Marković; Z Korandová; J Houštěk; T Mráček
Journal:  Physiol Res       Date:  2020-11-02       Impact factor: 1.881

Review 6.  Glycogen metabolism in humans.

Authors:  María M Adeva-Andany; Manuel González-Lucán; Cristóbal Donapetry-García; Carlos Fernández-Fernández; Eva Ameneiros-Rodríguez
Journal:  BBA Clin       Date:  2016-02-27

7.  Ketogenic diet in pyruvate dehydrogenase complex deficiency: short- and long-term outcomes.

Authors:  Kalliopi Sofou; Maria Dahlin; Tove Hallböök; Marie Lindefeldt; Gerd Viggedal; Niklas Darin
Journal:  J Inherit Metab Dis       Date:  2017-01-18       Impact factor: 4.982

8.  Selection and Characterization of Palmitic Acid Responsive Patients with an OXPHOS Complex I Defect.

Authors:  Tom E J Theunissen; Mike Gerards; Debby M E I Hellebrekers; Florence H van Tienen; Rick Kamps; Suzanne C E H Sallevelt; Elvira N M M-D Hartog; Hans R Scholte; Robert M Verdijk; Kees Schoonderwoerd; Irenaeus F M de Coo; Radek Szklarczyk; Hubert J M Smeets
Journal:  Front Mol Neurosci       Date:  2017-10-18       Impact factor: 5.639

9.  Beneficial effect of feeding a ketogenic diet to mothers on brain development in their progeny with a murine model of pyruvate dehydrogenase complex deficiency.

Authors:  Lioudmila Pliss; Urvi Jatania; Mulchand S Patel
Journal:  Mol Genet Metab Rep       Date:  2016-04-22

10.  Ketogenic Diet in Refractory Childhood Epilepsy: Starting With a Liquid Formulation in an Outpatient Setting.

Authors:  Amerins Weijenberg; Margreet van Rijn; Petra M C Callenbach; Tom J de Koning; Oebele F Brouwer
Journal:  Child Neurol Open       Date:  2018-05-29
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.